glp-1 and type 2 diabetes GLP1-GIP receptor co-agonists: a promising evolution in the treatment of | Acta Diabetologica GLP-1 receptor agonists | How

Bariatric surgery in proper candidates can be effective and safe for improving steatosis, inflammation and to a lesser degree liver fibrosis and must be carefully evaluated in individuals with cirrhosis [33, 34]

A random forest classification model was applied on the16S rRNA abundance analysis, revealing that Ruminococcus gnavus, Clostridium ramosum, and Bifidobacterium longum were highly enriched in gut microbiota composition during the tolerant (smooth) state compared to the rejection state in post-transplantation period (Figure 1A)

Initially developed for managing type 2 diabetes, semaglutide has since been approved for weight loss and is now widely prescribed for both conditions

Review best time of day to take semaglutide to minimize nausea through timing optimization

D., Shamshoum, H., Peppler, W

Data from RCTs largely support the ability of GLP-1 medicines to reduce rates of MACE in people with T2D, 88 and a single trial demonstrates reduced rates of MACE in semaglutide-treated patients with overweight or obesity